Discovery of reversible and covalent TEAD 1 selective inhibitors MSC-1254 and MSC-5046 based on one scaffold

Bioorg Med Chem Lett. 2024 Dec 1:114:129981. doi: 10.1016/j.bmcl.2024.129981. Epub 2024 Oct 5.

Abstract

The Transcriptional Enhanced Associated Domain (TEAD) family of transcription factors are key components of the Hippo signalling family which play a crucial role in the regulation of cell proliferation, differentiation and apoptosis. The identification of inhibitors of the TEAD transcription factors are an attractive strategy for the development of novel anticancer therapies. A HTS campaign identified hit 1, which was optimised using structure-based drug design, to deliver potent TEAD1 selective inhibitors with both a reversible and covalent mode of inhibition. The preference for TEAD1 could be rationalised by steric differences observed in the lower pocket of the palmitoylation-site between subtypes, with TEAD1 having the largest available volume to accommodate substitution in this region.

Keywords: Hippo pathway; Oncology; TEAD inhibitor; TEAD selectivity.

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • DNA-Binding Proteins* / antagonists & inhibitors
  • DNA-Binding Proteins* / metabolism
  • Dose-Response Relationship, Drug
  • Drug Discovery
  • Humans
  • Molecular Structure
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / metabolism
  • Structure-Activity Relationship
  • TEA Domain Transcription Factors*
  • Transcription Factors* / antagonists & inhibitors
  • Transcription Factors* / metabolism

Substances

  • TEA Domain Transcription Factors
  • Transcription Factors
  • DNA-Binding Proteins
  • TEAD1 protein, human
  • Nuclear Proteins
  • Antineoplastic Agents